A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Clinical trial NCT01940497 · COMPLETED
Trial details
- NCT number
- NCT01940497
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-15
- Primary completion
- 2016-04-05
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.